Alembic pharmaceuticals Limited has established a new subsidiary in the Philippines as part of its international expansion strategy. The company informed the stock exchanges about the incorporation of Alembic Lifesciences Philippines Inc. on April 22, 2026, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Subsidiary Details and Capital Structure

The newly incorporated subsidiary has been established with substantial initial capital to support its operations in the Philippine market.

Strategic Objectives and Business Focus

The subsidiary has been incorporated to explore new business opportunities in the Philippines geography. The primary objective is to promote, sell and distribute pharmaceutical products of the parent company in the Philippine market. This expansion aligns with Alembic Pharmaceuticals' strategy to strengthen its presence in international markets and tap into the growing pharmaceutical sector in Southeast Asia.

Regulatory Compliance and Industry Classification

The incorporation falls under the pharmaceuticals industry classification, maintaining alignment with the parent company's core business operations. The establishment of this subsidiary does not require any specific governmental or regulatory approvals beyond the standard incorporation procedures. Since this is a newly incorporated entity with no prior business history, the company has classified various acquisition-related parameters as not applicable.

Investment Structure

The investment in the Philippine subsidiary represents a strategic move through share capital investment rather than acquisition of an existing entity. The company has structured the investment to maintain significant control with 99.99% shareholding in Alembic Lifesciences Philippines Inc. This ownership structure ensures complete operational control while establishing a local presence in the Philippine pharmaceutical market.

The subsidiary is positioned to commence operations in the pharmaceutical distribution space, leveraging the parent company's product portfolio and expertise in the pharmaceutical sector.

Cupid Limited has initiated the Second 100-Day Campaign 'Saksham Niveshak' to facilitate dividend claims and KYC updates for shareholders, following directives from regulatory authorities. The company published regulatory intimation on April 17, 2026, to inform shareholders about this important initiative for unclaimed dividend recovery.

Campaign Overview and Objectives

The Investor Education and Protection Fund Authority (IEPFA) and Ministry of Corporate Affairs (MCA) requested companies through their circular dated March 27, 2026, to launch the Second 100-Day Campaign 'Saksham Niveshak'. The campaign specifically targets shareholders whose dividends remain unclaimed or unpaid, with emphasis on KYC updation and related compliance measures.

The objective of this initiative is to encourage shareholders to update their KYC details, bank mandates, and contact information to facilitate direct payment of unclaimed and unpaid dividends to rightful shareholders and prevent transfer to IEPF.

Documentation Requirements

The company has outlined specific forms and documents required for shareholders to claim their unpaid dividends:

Since dividend on shares is only payable in electronic mode, dividend will only be credited in shareholder's bank account after updating the required information and documents.

Process for Different Share Holdings

The company has outlined specific procedures for shareholders based on how they hold their shares:

Physical Share Holdings

Shareholders holding shares in physical form must submit applicable forms along with supporting documents to the company's Registrar and Share Transfer Agent.

Demat Share Holdings

For shares held in electronic form, shareholders need to update their KYC and other details with their respective Depository Participants (DP) to claim unclaimed dividends.

Documentation and Resources

The company has made required forms easily accessible to shareholders through their website at https://www.cupidlimited.com/kyc-forms-for-shareholders/ . Shareholders must fill in and deliver physical copies of these forms to the RTA at the specified address.

Regulatory Compliance

The intimation was issued under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Saurabh V. Karmase signed the regulatory intimation dated April 17, 2026, which was submitted to both BSE Limited and National Stock Exchange of India Ltd.

Call to Action

Cupid Limited encourages all shareholders to act promptly and submit their documents before July 9, 2026, to safeguard their entitlement and ensure compliance with statutory requirements. The initiative aims to prevent shareholders' dividends from being transferred to IEPF by ensuring proper documentation and contact information updates.